Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Aging01:26

Aging

37
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
37
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

65
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
65
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML.

Blood advances·2026
Same author

Dual CDK2 and CDK4/6 inhibition suppresses Rb/E2F signaling and enhances anti-leukemic activity in acute myeloid leukemia.

Haematologica·2026
Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026
Same author

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

HMA + venetoclax triplet regimens for the initial treatment of AML in adults- CONTRA.

Blood advances·2026
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2025

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.3K

AML in the Elderly - When less may be more.

Eric S Winer1, Richard M Stone2

  • 1Dana-Farber Cancer Center, 450 Brookline Ave, Boston, MA, 02215, USA. erics_winer@dfci.harvard.edu.

Current Oncology Reports
|October 17, 2024
PubMed
Summary
This summary is machine-generated.

Older adults with acute myeloid leukemia (AML) benefit from personalized treatment strategies. Novel targeted therapies offer less toxic and more effective options, improving outcomes for this patient group.

Keywords:
Acute Myeloid LeukemiaElderly AMLGeriatric AssessmentsHypomethylating AgentsOlder InductionTargeted Therapy

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Multi-Modal Home Sleep Monitoring in Older Adults
07:40

Multi-Modal Home Sleep Monitoring in Older Adults

Published on: January 26, 2019

7.6K

Related Experiment Videos

Last Updated: Jun 10, 2025

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

7.3K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Multi-Modal Home Sleep Monitoring in Older Adults
07:40

Multi-Modal Home Sleep Monitoring in Older Adults

Published on: January 26, 2019

7.6K

Area of Science:

  • Hematology
  • Geriatric Medicine
  • Oncology

Background:

  • Acute myeloid leukemia (AML) presents unique challenges in older patients.
  • Treatment decisions for elderly AML patients require careful consideration of their specific biological and clinical profiles.

Purpose of the Study:

  • To evaluate the distinct biological and clinical features of AML in older individuals.
  • To highlight the importance of pre-treatment assessments for personalized care in elderly AML patients.
  • To discuss the evolving treatment landscape from intensive to non-intensive therapies.

Main Methods:

  • Review of geriatric assessments and genetic data for predictive treatment guidance.
  • Analysis of recent FDA-approved targeted therapies for AML.
  • Comparison of novel therapies with conventional chemotherapy in older adults.

Main Results:

  • Geriatric and genetic data significantly aid in treatment selection for AML.
  • Nine new targeted therapies, primarily small molecule inhibitors, have been approved for AML.
  • Older AML patients can now receive less toxic treatments with comparable or superior efficacy.
  • TP53 mutant AML remains a challenge, but new agents offer future hope.

Conclusions:

  • Individualized treatment approaches are crucial for older AML patients.
  • Novel targeted therapies represent a significant advancement, offering improved outcomes and reduced toxicity.
  • Ongoing research and development of new agents promise further improvements for elderly AML patients.